FIGURE 1. Structural modifications to glabridin improvein vivo weight-reduction effect and chemical stability. (A)
Schematic of development of HSG4112 from glabridin (B-C) HFD-mice (n = 4
for non-vehicle groups, n = 2 for vehicle group) were orally
administered with vehicle or glabridin-derivatives (150
mg·kg-1·day-1) for 4-6 weeks for
screening purpose in (B) hydrogenation, (C) etherification and (D) chain
elongation steps. Data represent mean only, without statistical
analysis. For (E) enantiomerization, n = 5 per group with
50mg·kg-1·day-1 dosage. Data
represent mean ± SEM. ***P < 0.001; two-way ANOVA with
Tukey’s multiple comparison test. (F, G) Degradation of glabridin and
HSG4112 was measured by HPLC in (F) acidic solution – 1% hydrochloride
methanol solution (v/v%) and in (G) basic solution – 1% sodium
hydroxide methanol solution (w/v%). Three replicates were performed.
Data represent mean ± SD; error bar is not visible because of negligible
deviance. ***P < 0.001; two-way ANOVA with Sidak’s
multiple comparison test.